Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?

Immune checkpoint inhibitors (ICIs) have completely reshaped the treatment of many malignancies, with remarkable improvements in survival outcomes. In ovarian cancer (OC), however, this emerging class of drugs has not yet found a favorable use due to results from phase I and II studies, which have n...

Descripción completa

Detalles Bibliográficos
Autores principales: Musacchio, L., Cicala, C.M., Camarda, F., Ghizzoni, V., Giudice, E., Carbone, M.V., Ricci, C., Perri, M.T., Tronconi, F., Gentile, M., Salutari, V., Scambia, G., Lorusso, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294238/
https://www.ncbi.nlm.nih.gov/pubmed/35849879
http://dx.doi.org/10.1016/j.esmoop.2022.100536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294238/
https://www.ncbi.nlm.nih.gov/pubmed/35849879
http://dx.doi.org/10.1016/j.esmoop.2022.100536

Ejemplares similares